Until now, it is impossible to identify a fatal traumatic brain injury (TBI) before post-mortem radiological investigations or an autopsy take place. It would be preferable to have an additional diagnostic tool such as post-mortem biochemistry to get greater insight into the pathological pathways and survival times after sustaining TBI. Cerebrospinal fluid (CSF) and serum samples of 84 autopsy cases were collected from forensic autopsies with post-mortem intervals (PMI) of up to 148 h. The cases were categorized into a fatal TBI case group (n = 42) and non-TBI controls (n = 42). The values of glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), and neutrophil gelatinase-associated lipocalin (NGAL) were analyzed by means of quantitative chemiluminescent multiplex immunoassays. The main results indicate that the usage of liquid samples with good macroscopic quality is more relevant for meaningful biomarker analyses than the length of the PMI. All three proteins were shown to differentiate TBI fatalities from the controls in CSF. In serum, only GFAP could be shown to be able to identify TBI cases. This study is the first approach to measure the three proteins together in CSF and serum in autopsy cases. Determined threshold values may differentiate between fatal TBI and control cases. The presented results emphasize the possible use of post-mortem biochemistry as a supplemental tool in everyday forensic routine.
Get full access to this article
View all access options for this article.
References
1.
FaulM., and CoronadoV. (2015). Epidemiology of traumatic brain injury. Handb. Clin. Neurol., 127, 3–13.
2.
VázquezM.D., Sáncehz-RodriguezF., OsunaE., DiazJ., CoxD.E., Pérez-CárcelesM.D., MartinezP., LunaA., and PounderD.J. (1995). Creatine kinase BB and neuron-specific enolase in cerebrospinal fluid in the diagnosis of brain insult. Am. J. Forensic Med. Pathol., 16, 210–214.
3.
MimasakaS., HashiyadaM., NataM., and FunayamaM. (2001). Correlation between serum IL-6 levels and death: usefulness in diagnosis of “traumatic shock”?. Tohuko. J. Exp. Med., 193, 319–324.
4.
LiD.R., ZhuB.L., IshikawaT., ZhaoD., MichiueT., and MaedaH. (2006). Postmortem serum protein S100B levels with regard to the cause of death involving brain damage in medicolegal autopsy cases. Legal Med. 8, 71–77.
5.
LiD.R., MichiueT., ZhuB.L., IshikawaT., QuanL., ZhaoD., YoshidaC., ChenJ.H., WangQ., KomatsuA., AzumaY., and MaedaH. (2009). Evaluation of postmortem S100B levels in the cerebrospinal fluid with regard to the cause of death in medicolegal autopsy. Legal Med. Suppl., 1, S273–S275.
6.
OndruschkaB., PohlersD., SommerG., SchoberK., TeupserD., FrankeH., and DreßlerJ. (2013). S100B and NSE as useful postmortem biochemical markers of traumatic brain injury in autopsy cases. J. Neurotrauma, 30, 1862–1871.
7.
SofronieyM.V., and VintersH.V. (2010) Astrocytes: biology and pathology. Acta Neuropathol., 119, 7–35.
8.
HerrmannM., VosP., WunderlichM.T., de BruijnC.H.M.M., and LamersK.J.B. (2000). Release of glial tissue-specific proteins after acute stroke. A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke, 31, 2670–2677.
9.
FrankeH., VerkhratskyA., BurnstockG., and IllesP. (2012). Pathophysiology of astroglial purinergic signalling. Purinergic Signal. 8, 629–657.
10.
YangZ., and WangK. (2015). Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 38, 364–374.
11.
Di PietroV., AmoriniA.M., LazzarinoG., YakoubK.M., D'UrsoS., LazzarinoG., and BelliA. (2015). S100B and glial fibrillary acidic protein as indexes to monitor damage severity in an in vitro model of traumatic brain injury. Neurochem. Res., 40, 991–999.
12.
MettingZ., WilczakN., RodigerL.A., SchaafJ.M., and van der NaaltJ. (2012). GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology, 78, 1428–1433.
13.
PapaL., SilvestriS., BrophyG.M., GiordanoP., FalkJ.L., BragaC.F., TanC.N., AmeliN.J., DemeryJ.A., DixitN.K., MendesM.E., HayesR.L., WangK.K., and RobertsonC.S. (2014). GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J. Neurotrauma, 31, 1815–1822.
14.
PelinkaL.E., KroepflA., SchmidhammerR., KrennM., BuchingerW., RedlH., and RaabeA. (2004). Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma, 57, 1006–1012.
15.
ChenA., XiongL.J., TongY., and MaoM. (2013). The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed. Rep., 1, 167–176.
PardridgeW.M. (2002). Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv. Exp. Med. Biol., 513, 397–430.
18.
BurdaJ.E., BernsteinA.M., and SofroniewM.V. (2016). Astrocyte roles in traumatic brain injury. Exp. Neurol., 275, 305–315.
19.
Chacón-FernándezP., SäuberliK., ColzaniM., MoreauT., GhevaertC., and BardeY.A. (2016). Brain-derived neurotrophic factor in megakaryocytes. J. Biol. Chem., 291, 9872–9881.
20.
YamamotoH., and GurneyM.E. (1990). Human platelets contain brain-derived neurotrophic factor. J. Neurosci., 10, 3469–3478.
21.
LaskeC., StranskyE., LeyheT., EschweilerG.W., WittorfA., RichartzE., BartelsM., BuchkremerG., and SchottK. (2006). Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm., 113, 1217–1224.
22.
O'BryantS.E., HobsonV., HallJ.R., WaringS.C., ChanW., MassmannP., LacritzL., CullumC.M., Diaz-ArrastiaR., and Texas Alzheimer's Research Consortium. (2009). Brain-derived neurotrophic factor levels in Alzheimer's disease. J. Alzheimers Dis., 17, 337–341.
23.
WuD. (2005). Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx. 2, 120–128.
24.
da Silva MeirellesL., SimonD., and RegnerA. (2017). Neurotrauma: the crosstalk between neurotrophins and inflammation in the acutely injured brain. Int. J. Mol. Sci., E1082.
25.
BolignanoD., LacquanitiA., CoppolinoG., DonatoV., CampoS., FazioM.R., NicociaG., and BuemiM. (2009). Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol., 4, 337–344.
26.
ZhaoJ., ChenH., ZhangM., ZhangY., QianC., LiuY., HeS., ZouY., and LiuH. (2016). Early expression of serum neutrophil gelatinase-associated lipocalin (NGAL) is associated with neurological severity immediately after traumatic brain injury. J. Neurol. Sci., 368, 392–398.
27.
ChakrabortyS., KaurS., GuhaS., and BatraS.K. (2012). The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta, 1826, 129–169.
28.
WongT.H., KrishnaswamyG., NadkarniN.V., NguyenH.V., LimG.H., BautistaD.C., ChiuM.T., ChowK.Y., and OngM.E. (2016). Combining the new injury severity score with an anatomical polytrauma injury variable predicts mortality better than the new injury severity score and the injury severity score: a retrospective cohort study. Scand. J. Trauma Resusc. Emerg. Med., 24, 25.
29.
BenjaminiY., and HochbergY. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol., 57, 289–300.
30.
LinH., LuoY., SunQ., ZhangJ., TuoY., ZhangZ., WangL., DengK., ChenY., HuangP., and WangZ. (2018). Identification of pulmonary edema in forensic autopsy cases of sudden cardiac death using Fourier transform infrared microspectroscopy: a pilot study. Anal. Chem., 90, 2708–2715.
31.
MaedaH., ZhuB.L., IshikawaT., QuanL., and MichiueT. (2009). Significance of postmortem biochemistry in determining the cause of death. Legal Med. 11, S46–S49.
32.
PalmiereC., BardyD., LetovanecI., ManginP., AugsburgerM., VenturaF., IglesiasK., and WernerD. (2013). Biochemical markers of fatal hypothermia. Forensic Sci. Int., 226, 54–61.
33.
OndruschkaB., SchuchS., PohlersD., FrankeH., and DreßlerJ. (2018). Acute phase response after fatal traumatic brain injury. Int. J. Legal Med., 132, 531–539.
34.
SieberM., DreßlerJ., FrankeH., PohlersD., and OndruschkaB. (2018). Post-mortem biochemistry of NSE and S100B: a supplemental tool for detecting a lethal traumatic brain injury?. J. Forensic Leg. Med., 55, 65–73.
35.
SchiffL., HadkerN., WeiserS., and RauschC. (2012). A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol. Diagn. Ther., 16, 79–92.
36.
PlogB.A., DashnawM.L., HitomiE., PengW., LiaoY., LouN., DeaneR., and NedergaardM. (2015). Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci., 35, 518–526.
37.
WoodcockT. and Morganti-KossmannM.C. (2013). The role of markers of inflammation in traumatic brain injury. Front. Neurol., 4, 4–18.
38.
ZetterbergH., TanriverdiF., UnluhizarciK., SelcukluA., KelestimurF., and BlennowK. (2009). Sustained release of neuron-specific enolase to serum in amateur boxers. Brain Inj. 23, 723–726.
39.
RosénC., MattssonN., JohanssonP.M., AndreassonU., WallinA., HanssonO., JohanssonJ.O., LamontJ., SvenssonJ., BlennowK., and ZetterbergH. (2011). Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front. Aging Neurosci., 3, 1–9.
40.
TakalaR.S., PostiJ.P., RunttiH., NewcombeV.F., OuttrimJ., KatilaA.J., FrantzénJ., Ala-SeppäläH., KyllönenA., MaanpääH.R., TallusJ., HossainM.I., ColesJ.P., HutchinsonP., van GilsM., MenonD.K., andTenovuoO. (2016). Glial fibrillary acidic protein and ubiquitin c-terminal hydrolase-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 87, 8–20.
41.
PostiJ.P., HossainI., TakalaR.S., LiedesH., NewcombeV., OuttrimJ., KatilaA.J., FrantzénJ., Ala-SeppäläH., ColesJ.P., KyllönenA., MaanpääH.R., TallusJ., HutchinsonP.J., van GilsM., MenonD.K, and TenovuoO. (2017). Glial fibrillary acidic protein and ubiquitin c-terminal hydrolase-L1 are not specific biomarkers for mild CT-negative traumatic brain injury. J. Neurotrauma, 34, 1427–1438.
42.
CzeiterE., MondelloS., KovacsN., SandorJ., GabrielliA., SchmidK., TortellaF., WangK.K., HayesR.L., BarzoP., EzerE., DocziT., and BukiA. (2012). Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J. Neurotrauma, 29, 1770–1778.
43.
FaillaM.D., ConleyY.P., and WagnerA.K. (2016). Brain-derived neurotrophic factor (BDNF) in traumatic brain injury-related mortality: interrelationships between genetics and acute systemic and central nervous system BDNF profiles. Neurorehabil. Neural. Repair., 30, 83–93.
44.
HanriederJ., WetterhallM., EnbladP., HilleredL., and BergquistJ. (2009). Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J. Neurosci. Methods, 177, 469–478.
45.
KawataK., LiuC.Y., MerkelS.F., RamirezS.H., TierneyR.T., and LangfordD. (2016). Blood biomarkers for brain injury: what are we measuring?. Neurosci. Biobehav. Rev., 68, 460–473.
46.
PapaL., and WangK.K.W. (2017). Raising the bar for traumatic brain injury biomarker research: methods make a difference. J. Neurotrauma, 34, 2187–2189.
47.
KimH.J., TsaoJ.W., and StanfillA.G. (2018). The current state of biomarkers of mild traumatic brain injury. J.C.I. Insight. Available at: https://insight.jci.org/articles/view/97105. Last accessed March7, 2018.
48.
GoedeA., DreßlerJ., SommerG., SchoberK., FrankeH., and OndruschkaB. (2015). Wundalterdiagnostik nach letalem Schädel-Hirn-Trauma. Rechtsmedizin, 25, 261–267.
49.
McMahonP.J., PanczykowskiD.M., YueJ.K., PuccioA.M., InoueT., SoraniM.D., LingsmaH.F., MaasA.I., ValadkaA.B., YuhE.L., MukherjeeP., ManleyG.T., OkonkwoD.O., and TRACK-TBI Investigators. (2015). Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDF biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J. Neurotrauma, 32, 527–533.
50.
GhoneimF.M., KhalafH.A., ElsamanoudyA.Z., Abo El-KhairS.M., HelalyA.M., MahmoudE.H.M., and ElshafeyS.H. (2015). Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease. Int. J. Clin. Exp. Pathol., 8, 7710–7728.
51.
DasA., and ChowdhuryR. (2017). Searching cause of death through different autopsy methods: a new initiative. J. Family Med. Prim. Care., 6, 191–195.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
